How can I optimize treatment for a restless‑legs syndrome patient taking iron 600 mg daily, gabapentin 300 mg as needed, and ropinirole who reports inadequate symptom relief?

Discontinue ropinirole and transition to gabapentin or pregabalin as scheduled daily therapy, while optimizing iron status

Your patient is on a suboptimal regimen that contradicts current best evidence—ropinirole should be discontinued due to augmentation risk, gabapentin needs to be scheduled (not PRN), and iron supplementation requires verification of appropriate dosing and monitoring.

Immediate Assessment Required

Before making treatment changes, check:

• Ferritin level (target >100 ng/mL, treat if <75 ng/mL)
• Transferrin saturation (treat if <20%)
• Current ropinirole dose and duration of use
• Whether symptoms have worsened, spread to arms, or occur earlier in the day (signs of augmentation)

Why This Regimen Is Failing

Problem 1: Ropinirole Is No Longer Recommended

The 2025 AASM guidelines suggest against the standard use of ropinirole (conditional recommendation, moderate certainty) 1. While it may provide short-term symptom relief, the long-term risk of augmentation—a paradoxical worsening where RLS symptoms become more severe, occur earlier in the day, and spread to other body parts—makes it unsuitable for chronic management 1.

Problem 2: Gabapentin Is Being Used Incorrectly

Gabapentin 300 mg "as needed" is inadequate. The AASM strongly recommends gabapentin as first-line therapy (strong recommendation, moderate certainty) 1, but it requires scheduled daily dosing to be effective. Typical therapeutic doses range from 1200-2400 mg/day divided into 2-3 doses, with the largest dose 1-2 hours before bedtime 2.

Problem 3: Iron Supplementation May Be Insufficient

"Horizont 600 mg" (likely ferrous sulfate or similar oral iron) may not be adequate. The guidelines recommend checking iron parameters and considering IV iron formulations (ferric carboxymaltose, iron dextran, or ferumoxytol) for more robust repletion, particularly if ferritin remains <75 ng/mL despite oral supplementation 1.

Recommended Treatment Algorithm

Step 1: Optimize Iron First (Weeks 1-2)

• Check ferritin and transferrin saturation
• If ferritin <75 ng/mL: Consider **IV ferric carboxymaltose** (strong recommendation) 1 or continue/increase oral iron with goal ferritin >100 ng/mL
• If already adequate, proceed to Step 2

Step 2: Initiate Scheduled Alpha-2-Delta Ligand (Weeks 2-6)

Choose ONE of the following first-line agents (all have strong AASM recommendations) 1:

Option A: Gabapentin (already partially on board)

• Start 300 mg nightly, 1-2 hours before bed
• Increase by 300 mg every 3-5 days
• Target dose: 1200-2400 mg/day (divided doses, largest at bedtime)
• Maximum studied: 3600 mg/day

Option B: Pregabalin (alternative if gabapentin poorly tolerated)

• Start 75 mg nightly, 1-2 hours before bed
• Increase by 75 mg every 3-5 days
• Target dose: 150-450 mg/day
• Better bioavailability than gabapentin

Option C: Gabapentin enacarbil (if available/affordable)

• Start 600 mg once daily at 5 PM
• Can increase to 1200 mg if needed
• Extended-release formulation with more consistent absorption

Step 3: Taper Ropinirole SLOWLY (Weeks 4-8)

Critical caveat: Do NOT stop ropinirole abruptly—this causes severe rebound RLS and insomnia 3, 4.

Only begin taper once adequate symptom control achieved with alpha-2-delta ligand:

• Reduce ropinirole by 0.25 mg every 5-7 days
• If symptoms worsen during taper, temporarily increase alpha-2-delta ligand dose
• Complete discontinuation may take 4-8 weeks
• Some patients require temporary opioid bridge (see below) if rebound is severe

Step 4: If Refractory After Above Steps

If symptoms persist despite optimized iron and maximum tolerated alpha-2-delta ligand:

Add low-dose opioid (conditional recommendation) 1:

• Extended-release oxycodone 5-10 mg nightly, OR
• Tramadol 50-100 mg nightly
• Monitor for tolerance, dependence (though risk is lower in RLS than pain populations) 3

Alternative: Dipyridamole 200 mg twice daily (conditional recommendation) 1

Common Pitfalls to Avoid

1. Don't continue ropinirole long-term: Augmentation occurs in 30-60% of patients on dopamine agonists, often within 6-12 months 3, 5

2. Don't use gabapentin PRN: Alpha-2-delta ligands require steady-state levels; PRN dosing is ineffective

3. Don't ignore iron even if "normal": RLS patients need higher ferritin targets (>100 ng/mL) than general population (>30 ng/mL) 1, 6

4. Don't taper ropinirole too quickly: Rebound can be worse than original symptoms; very slow taper essential 3

5. Don't forget exacerbating factors: Review medications (SSRIs, antihistamines, antipsychotics), caffeine/alcohol use, and screen for sleep apnea 1

Expected Timeline

• Weeks 1-2: Iron optimization begins
• Weeks 2-4: Alpha-2-delta ligand titration to therapeutic dose
• Weeks 4-8: Slow ropinirole taper once symptom control achieved
• Week 8+: Maintenance on alpha-2-delta ligand ± iron, ropinirole discontinued

This approach aligns with the 2025 AASM guidelines' paradigm shift away from dopaminergic therapy toward augmentation-aware, iron-conscious, non-dopaminergic first-line treatment 5, 6. The goal is durable long-term symptom control without the progressive worsening that dopamine agonists inevitably produce.